DailyIQ
Last updatedjust now

UTHR·United Therapeutics Corporation

$493.66
-0.97 (-0.20%)
High
$497.70
Open
$497.70
Market Cap
21.22B
52W High
$625.00
Low
$491.25
P. Close
$493.66
P/E
16.18
52W Low
$403.00
Fwd P/E
16.48
DailyIQ Est.
$685.63
Inst. Ownership
3.6%
Short Interest
4.80%
Days to Cover
4.8
Technical Score (1D)
23
SELL
News Sentiment
58
BULLISH
United Therapeutics has just been highlighted in a ChartMill “high‑quality, debt‑free” screen, a new development that arrives just 1.3 hours ago. The screen flags the company’s 28.45 % ROIC and strong EBIT growth, underscoring its robust earnings quality and low leverage. Because the firm carries zero debt, the rating signals that UTHR has ample financial flexibility to fund growth or weather downturns, which may make it more attractive to risk‑averse investors in the near term. This fresh endorsement could lift demand for the stock over the next 1–10 trading days as traders reassess its risk‑adjusted return profile. The lack of an immediate catalyst means the impact will likely be gradual, but the screen may prompt a re‑evaluation of the company’s valuation multiples. Watch for the upcoming earnings release, as any deviation from the strong EBIT trend could alter the narrative. Also keep an eye on regulatory developments in the pulmonary hypertension space, since UTHR’s core product portfolio is highly sensitive to approval changes. Finally, monitor any shifts in the broader biotech sector that could influence investor sentiment toward high‑quality, debt‑free names.
Earnings Summary
United Therapeutics Corporation is a specialty biotechnology firm focused on commercializing therapies for pulmonary arterial hypertension (PAH) and other life‑threatening conditions, operating within the healthcare drug manufacturing sector. In Q4 2024, the company reported EPS of $6.19 against an estimate of $6.27, slightly below expectations, while revenue of $735.9 million matched the estimate; in Q4 2025, EPS rose to $7.70 beating the $7.33 estimate, but revenue fell to $790.2 million from an estimated $829.3 million, indicating a revenue dip despite earnings growth. The most recent Q2 2026 EPS of $7.27 surpassed the $6.97 estimate, and revenue of $783.3 million was below the $821.8 million estimate, continuing a pattern of earnings beats amid revenue softness. Historically, United Therapeutics has shown a YoY revenue decline in the most recent quarters, yet EPS has consistently outperformed analyst forecasts, reflecting pricing power and cost efficiencies in its PAH portfolio. Recent news reports the FDA’s acceptance of the supplemental NDA for Tyvaso in idiopathic pulmonary fibrosis, a regulatory milestone that could broaden the drug’s market and add a new revenue stream once approved; the company also received acceptance for its ralinepag NDA, with positive Phase III data, signaling potential future growth. Investors should watch for the FDA’s final approval decisions in the coming months, as these will dictate the timing of new revenue recognition, and monitor any updates on commercial rollout plans or pricing strategies, which could materially influence the company’s earnings trajectory.

EPS

EstBeatMiss
$5.96$6.45$6.95$7.44$7.93Q4'24Q4'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$6.96 - -
Q2'26$6.97$7.27+4.3%
Q4'25$7.33$7.70+5.1%
Q4'24$6.27$6.19-1.2%

Revenue

EstBeatMiss
$722M$752M$783M$813M$843MQ4'24Q4'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$807M - -
Q2'26$822M$783M-4.7%
Q4'25$829M$790M-4.7%
Q4'24 - $736M -

Market Data

UTHR Stock Snapshot

SELL23/100
$493.66$0.97 (0.2%)
Market cap
21.22B
P/E ratio
16.2
Day range
$491.25 – $497.70
News sentiment
58/100 · Neutral
Analyst target
$664.33 (+34.6%)
Consensus
Buy · 24 analysts
52-week range+22.5% off low · -21.0% from high
$403.00$625.00
Price $493.66 DailyIQ Est. $685.63

UTHR is on the weaker side of its setup, with little confirmation for a reversal yet. Earnings and guidance carry more weight than macro data at this capitalisation.

Behaviour On Record

What UTHR's own history says about today's numbers

Realized volatility (21d)
22.9% 21st pct
Below its peak
-16.2%
vs 200-day average
-5.2%
Up days (1y)
47%

United Therapeutics Corporation is currently running 22.9% annualised volatility over the last 21 sessions. Measured against UTHR's own 13 years of daily returns rather than a market-wide average, that is the 21st percentile unusually subdued by its own history, against a typical reading of 29.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

UTHR is trading -16.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -29.5%, and the deepest was -41.1% in 2019. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -5.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 27th percentile a narrower gap than it typically runs. Over the past year UTHR closed higher on 47% of sessions, and it is currently 1 session into a rising streak.

On September specifically: over 13 years of records, UTHR finished the month higher 4 of 13 times, with a median return of -3.1% and an average of -2.5%. Its strongest month historically has been October at +5.8% on average, its weakest September at -2.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: UTHR has opened more than 2% away from the prior close in 124 of 3,267 sessions (3.8% of the time), with the largest gaps running +51.0% and -12.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-09-23 and 2026-09-21, split-adjusted, recomputed daily. Percentiles are against UTHR's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of UTHR's sector?

United Therapeutics Corporation sits in the Health Care sector, currently ranked 5th of 11 GICS sectors by relative-strength rotation score (improving).

Sector rank
#5 of 11
Sector state
Improving
Sector rotation score
80

Options Market

What is the options market pricing for UTHR?

CallsPuts

For United Therapeutics Corporation's nearest expiry (2026-10-16, 25 days out), open interest is roughly balanced between puts and calls (put/call ratio of 1.01), with at-the-money implied volatility around 39.4%. The options market is pricing roughly a ±9.4% move by that expiry — a range of about $447.32–$539.82.

Put/call ratio (2026-10-16)
1.01
ATM implied volatility
39.4%
Total open interest
30,264
Expected move by 2026-10-16
±9.4% ($447.32–$539.82)

Analyst Rating Changes

Are analysts turning bullish or bearish on UTHR?

RBC Capital most recently reiterated its rating on United Therapeutics Corporation to Outperform on Aug 6, 2026 with a price target of $677 (from $704). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
RBC CapitalOutperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 6, 2026RBC CapitalMaintainedOutperform$704 → $677
Jul 23, 2026JP MorganMaintainedOverweight$685 → $687
Jul 10, 2026B of A SecuritiesMaintainedNeutral$620 → $613
Jul 7, 2026RBC CapitalMaintainedOutperform$701 → $704
May 7, 2026RBC CapitalMaintainedOutperform$707 → $701
May 7, 2026Wells FargoUpgradeEqual-Weight → Overweight$575 → $738
Apr 10, 2026Morgan StanleyMaintainedEqual-Weight$471 → $519
Mar 31, 2026HC Wainwright & Co.MaintainedBuy$600 → $660
Mar 31, 2026Wells FargoMaintainedEqual-Weight$486 → $575
Mar 31, 2026B of A SecuritiesMaintainedNeutral$569 → $626
Mar 30, 2026TD CowenMaintainedBuy$575 → $660
Mar 23, 2026Wells FargoMaintainedEqual-Weight$466 → $486

UTHR Competitive Positioning

United Therapeutics Corporation (UTHR) is tracked alongside these names in Drug Manufacturers - Specialty & Generic on DailyIQ — ranked by market cap, with today's move alongside.